The study population comprised 578 patients (80% females) from our EA clinic with a median disease duration, 5.1 months (p25–p75: 6–8); median age, 53.6 years (41.9–66.1), 38% ACPA-positive, and 55% fulfilling 2010 criteria for rheumatoid arthritis. This evidence concerns the gene PRTN3 and rheumatoid arthritis.